OpenEvidence Pivot From Ads to Drugs

This signals a bid to move from selling attention to owning assets. OpenEvidence already has physician usage, medical literature distribution, and growing model infrastructure, but the Regeneron comparison points to a much bigger shift, using that data and software layer to pick drug targets, create its own rare cancer programs, and keep the downstream economics if any therapy works.1 2 3 4

• Regeneron is the relevant model because it is not just a software or services company. It is a fully integrated drug maker built around homegrown discovery technology, internal development, and ownership of approved medicines, especially in specialized disease areas including cancer and rare disease.4 5 6
• For OpenEvidence, the strategic logic is that a free clinician product can do more than sell ads. If doctors search, compare evidence, and eventually use OpenEvidence inside treatment workflows, that creates a front row seat to unmet needs in oncology that can inform which drug programs to pursue.1 2 3 7
• The hard part is that drug discovery is a different business from clinical software. Rare cancers are attractive because patient groups are smaller and unmet need is higher, but the FDA notes these programs are harder to study because trials are tougher to run and comparable standard treatments are often limited.5 8

If this works, OpenEvidence stops looking like a high margin medical media company and starts looking like a vertically integrated healthcare company with two engines, one that captures physician demand and one that turns that demand signal into proprietary therapies. That would push it toward biotech style value creation, where a single successful drug can matter more than years of ad revenue.1 2 4 6